ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2302

Forearm Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis

Nelson B. Watts1, Robin K. Dore2, Sanford Baim3, Gary Hattersley4, Greg Williams5, Yamei Wang4, Tamara D. Rozental6 and Meryl S. LeBoff7, 1Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, 2Univ of California, Los Angeles, CA, 3Rush Medical College, Chicago, IL, 4Radius Health, Inc., Waltham, MA, 5Clinical Development, Radius Health, Inc., Waltham, MA, 6Beth Israel Deaconess Medical Center, Boston, MA, 7Brigham and Women's Hospital, Boston, MA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Bone, Bone density, fractures and osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Wrist fractures are the most common fracture of the upper extremity and increase subsequent fracture risk in women with postmenopausal osteoporosis. Most wrist fractures occur at the ultradistal (UD) radius. Abaloparatide (ABL) is a selective activator of the PTH1 receptor signaling pathway that stimulates bone formation. In the ACTIVE phase 3 study, 18 months of ABL significantly increased bone mineral density (BMD) at the UD radius and maintained BMD at the 1/3 distal radius vs placebo (PBO) and teriparatide (TPTD). BMD effects were associated with a trend for numerically lower wrist fracture incidence for ABL vs TPTD (P=0.052). Women receiving ABL or PBO in ACTIVE were offered enrollment in the ACTIVExtend extension study in which both groups received 24 months of open-label alendronate (ALN) 70 mg/wk for a total of 43 months (18 months ABL or PBO, 1 month for reconsent, 24 months ALN). Our objective was to determine the efficacy of ABL followed by ALN (ABL/ALN) vs PBO/ALN on BMD at the UD radius over 43 months.

Methods: Forearm BMD data (ACTIVE baseline and month 43) were measured for 213 and 233 women in ABL/ALN and PBO/ALN groups, respectively. BMD was centrally analyzed and adjusted for machine differences. DXA scanner and baseline BMD were included as covariates. Wrist fracture event rates were estimated for the ACTIVExtend ITT population (558 ABL/ALN; 581 PBO/ALN) by KM method.

Results: Over the 18 months of the ACTIVE trial, BMD of the UD radius decreased in the placebo group but increased with ABL; these increases were maintained over the ALN extension (Figure). There were 15 women with wrist fractures in the ABL/ALN group (KM estimate: 2.8%) and 20 in the PBO/ALN group (3.6%). Although the number of wrist fractures was low, these fractures were numerically lower with ABL/ALN vs PBO/ALN (HR=0.77, 95% CI [0.39, 1.50], P=NS).

Conclusion: The BMD gains at the UD radius following treatment with ABL were maintained over the subsequent 24 months of treatment with ALN.  Wrist fracture risk was numerically lower with ABL/ALN vs PBO/ALN. These results, together with previous ACTIVE analyses, suggest that BMD of the UD radius, which is rich in trabecular bone, may be a better predictor of wrist fracture than the 1/3 distal radius.

 

 

 

 

 

Figure. Mean (± SE) Percent Change in Ultradistal Radius BMD from Baseline Through Month 43

Missing BMD data imputed using the method of last observation carried forward. ABL, abaloparatide; ALN, alendronate; SE, standard error.

 


Disclosure: N. B. Watts, Amgen Inc., 8,Shire Pharmaceutical, 8,AbbVie Inc., 5,Amgen Inc., 5,Janssen, 5,Radius Health, Inc, 5,Sanofi, 5; R. K. Dore, Radius Health, Inc, 8,Eli Lilly and Co., 5,Amgen Inc., 5; S. Baim, None; G. Hattersley, Radius Health, Inc, 3; G. Williams, Radius Health, Inc., 3; Y. Wang, Radius Health, Inc, 3; T. D. Rozental, None; M. S. LeBoff, NIH/NIAMS, 2,Amgen Inc., 1.

To cite this abstract in AMA style:

Watts NB, Dore RK, Baim S, Hattersley G, Williams G, Wang Y, Rozental TD, LeBoff MS. Forearm Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/forearm-bone-mineral-density-and-fracture-incidence-in-postmenopausal-women-with-osteoporosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/forearm-bone-mineral-density-and-fracture-incidence-in-postmenopausal-women-with-osteoporosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology